Altay Therapeutics
YC W20 · Active · Altay develops disease-modifying therapies targeting transcription…
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
 Ochre BioShared: liver disease, chronic liver, biotechActiveOther | Other | Active | YC +1W20 |
 Serna BioShared: small molecule, drug discovery, biotechActiveOther | Other | Active | YCW21 |
 Eris BiotechShared: small molecule, drug discovery, therapeuticsActiveOther | Other | Active | YCW24 |
 Encepheal TherapeuticsShared: small molecule, fda approved, drug discoveryInactiveOther | Other | Inactive | YCS19 |
 Origami Therapeutics, Inc.Shared: small molecule, drug discovery, therapeuticsActiveOther | Other | Active | YCW22 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
 Arpeggio BioShared: targeting transcription, drug discovery, biotechActiveAI | AI | Active | YCS19 |
 HepatxShared: chronic liver, liver disease, biotechActiveOther | Other | Active | YCS18 |
 AlixiaShared: drug discovery, therapeutics, biotechActiveOther | Other | Active | YCW22 |
 Gerostate AlphaShared: therapeutics, biotech, diseaseInactiveOther | Other | Inactive | YCS18 |
 Kernal BiologicsShared: approved therapy, fda approved, biotechActiveAI | AI | Active | YCS20 |
Also from W20 in AI
All of W20
About Altay Therapeutics
Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.
- YC batch
- W20 · Winter 2020
- Status, per YC
- Active
- Category
- AI
- Team size
- 6
- Location
- San Francisco, CA, USA; South San Francisco, CA, USA
- Checked
- 36m ago
YC tags: AI-powered Drug Discovery, Biotech, Therapeutics, Drug discovery
Altay Therapeutics: questions
Which YC batch was Altay Therapeutics in?
Altay Therapeutics was in Y Combinator's Winter 2020 batch (W20).
Is Altay Therapeutics still active?
Y Combinator lists Altay Therapeutics as active.
Where is Altay Therapeutics based?
Altay Therapeutics lists San Francisco, CA, USA; South San Francisco, CA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.